MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1053/j.ajkd.2016.02.052

Медицинская библиотека · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2016

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

Staplin Natalie, Haynes Richard, Herrington William G, Reith Christina, Cass Alan, Fellström Bengt, Jiang Lixin, Kasiske Bertram L, Krane Vera, Levin Adeera, Walker Robert, Wanner Christoph, Wheeler David C, Landray Martin J, Baigent Colin, Emberson Jonathan, SHARP Collaborative Group

СтатьяНаблюдательное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The absolute and relative importance of smoking to vascular and nonvascular outcomes in people with chronic kidney disease (CKD), as well its relevance to kidney disease progression, is uncertain.

STUDY

DESIGN

Observational study.

SETTING &

PARTICIPANTS

9,270 participants with CKD enrolled in SHARP.

PREDICTOR: Baseline smoking status (current, former, and never).

OUTCOMES: Vascular events, site-specific cancer, ESRD, rate of change in estimated glomerular filtration rate (eGFR), and cause-specific mortality.

RESULTS

At baseline, 1,243 (13%) participants were current smokers (median consumption, 10 cigarettes/day); 3,272 (35%), former smokers; and 4,755 (51%), never smokers. Median follow-up was 4.9 years. Vascular event rates were 36% higher for current than never smokers (2,317 events; relative risk [RR], 1.36; 95% CI, 1.19-1.55), reflecting increases in both atherosclerotic (RR, 1.49; 95% CI, 1.26-1.76) and nonatherosclerotic (RR, 1.25; 95% CI, 1.05-1.50) events. Cancer was 37% higher among current smokers (632 events; RR, 1.37; 95% CI, 1.07-1.76), with the biggest RRs for lung (RR, 9.31; 95% CI, 4.37-19.83) and upper aerodigestive tract (RR, 4.87; 95% CI, 2.10-11.32) cancers. For 6,245 patients not receiving dialysis at baseline, ESRD incidence did not differ significantly between current and never smokers (2,141 events; RR, 1.02; 95% CI, 0.89-1.17), nor did estimated rate of change in eGFR (current smokers, -1.77±0.14 [SE]; never smokers, -1.70±0.07mL/min/1.73m(2) per year). All-cause mortality was 48% higher among current smokers (2,257 events; RR, 1.48; 95% CI, 1.30-1.70), with significant increases in vascular (RR, 1.35; 95% CI, 1.07-1.69) and nonvascular (RR, 1.60; 95% CI, 1.34-1.91) causes of death, especially cancer (RR, 2.32; 95% CI, 1.58-3.40) and respiratory (RR, 2.25; 95% CI, 1.51-3.35) mortality.

LIMITATIONS: Smoking status not assessed during follow-up.

CONCLUSIONS

In this study of patients with CKD, smoking significantly increased the risks for vascular and nonvascular morbidity and mortality, but was not associated with kidney disease progression. The associations with vascular and neoplastic disease are in keeping with those observed in the general population and are likely modifiable by cessation.

Для цитирования: Staplin Natalie, Haynes Richard, Herrington William G, Reith Christina, Cass Alan, Fellström Bengt, Jiang Lixin, Kasiske Bertram L, Krane Vera, Levin Adeera, Walker Robert, Wanner Christoph, Wheeler David C, Landray Martin J, Baigent Colin, Emberson Jonathan, SHARP Collaborative Group. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2016. DOI: 10.1053/j.ajkd.2016.02.052.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.